We present a comprehensive ancestry-based prevalence and co-alteration landscape of genomic alterations and immunotherapy-associated biomarkers in patients withand-altered non-squamous (non-Sq) NSCLC.was the most frequently altered oncogene in European (EUR) and African (AFR), whilealterations ...
Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA_ERR_SRC_NOT_SUPPORTED Technical details :...
13, 2024 -- Tusamitamab ravtansine (tusa rav), an immunoconjugate, does not improve progression-free survival (PFS) in patients with previously treated advanced nonsquamous non-small cell lung cancer (NSCLC), according to a study presented at the International Association for the Study of ...
Roger M. Perlmutter, MD, PhD The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab (Keytruda) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non—small cell lung cancer (NS...
“Datopotamab deruxtecan is the only investigational therapy to show a clinically meaningful survival improvement in patients with previously treated nonsquamous [NSCLC] vs docetaxel, which has long been unsurpassed in this post-targeted treatment and post-immunotherapy setting,” Susan Galbraith, exec...
Corey J. Langer, MD, Perelman Center for Advanced Medicine, Hospital of the University of Pennsylvania, discusses current treatment strategies for patients with non-driver nonsquamous non-small cell lung cancer (NSCLC).
becoming the world’s first anti-PD-L1 monoclonal antibody that can be combined with chemotherapy as the first-line treatment of both squamous and non-squamous NSCLC patients. This further strengthens our confidence in the development of CS1001 and greatly expediate CStone’s commercialization ...
In an interview with Targeted Oncology, Jorge Nieva, MD, provided a recap of the recent ODAC meeting and explained his stance against further research for frontline sintilimab plus chemotherapy for the treatment of patients with nonsquamous NSCLC.
Background: Genetic variations in non-small cell lung cancer (NSCLC) have been shown potential impact on immune microenvironment, and associated with response odoi:10.2139/ssrn.3384916Dong, Zhong-yiBai, XueWang, JianTang, Xin-RanLiu, Li
Nivolumab (Opdivo) improved survival versus docetaxel in patients with pretreated nonsquamous non—small cell lung cancer (NSCLC) in the phase III CheckMate-057 trial, according to Bristol-Myers Squibb (BMS), which manufactures the PD-1 inhibitor. The study was stopped early after an independent ...